World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Gilead’s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster
Keywords:
Tags: Information Technology,
Gilead Sciences and Sovaldi for Hepatitis C
12/06/2013
Grouped Articles
F.D.A. Approves Pill to Treat Hepatitis C
New York Times 12/06/2013
Hepatitis C Pill Rockets Gilead Into Big Leagues
Wall Street Journal 07/24/2014
Gilead’s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster
New York Times 07/23/2014
Maker of Costly Hepatitis C Drug Sovaldi Strikes Deal on Generics for Poor Countries
New York Times 09/15/2014
Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries
Wall Street Journal 09/16/2014
AbbVie Pins Hopes on Hepatitis C Treatment
Wall Street Journal 12/18/2014
Gilead Sciences management
07/23/2014
Grouped Articles
Hepatitis C Pill Rockets Gilead Into Big Leagues
Wall Street Journal 07/24/2014
Gilead’s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster
New York Times 07/23/2014
Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries
Wall Street Journal 09/16/2014
CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs
Wall Street Journal 01/06/2015
Overheard: Gilead Needs More Tracks
Wall Street Journal 02/22/2015
Gilead Sciences strategies
07/23/2014
Grouped Articles
Hepatitis C Pill Rockets Gilead Into Big Leagues
Wall Street Journal 07/24/2014
Gilead’s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster
New York Times 07/23/2014
Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries
Wall Street Journal 09/16/2014
CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs
Wall Street Journal 01/06/2015
Overheard: Gilead Needs More Tracks
Wall Street Journal 02/22/2015
Gilead Sciences and the acquisition of Pharmasset for new drug with public health implications
11/22/2011
Grouped Articles
F.D.A. Approves Pill to Treat Hepatitis C
New York Times 12/06/2013
Gilead’s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster
New York Times 07/23/2014
Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries
Wall Street Journal 09/16/2014
Overheard: Gilead Needs More Tracks
Wall Street Journal 02/22/2015
Wall Street Journal 11/22/2011
Gilead's Risky Revival Procedure
Wall Street Journal 11/22/2011
Gilead Sciences performance
07/23/2014
Grouped Articles
Hepatitis C Pill Rockets Gilead Into Big Leagues
Wall Street Journal 07/24/2014
Gilead’s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster
New York Times 07/23/2014
Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries
Wall Street Journal 09/16/2014
CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs
Wall Street Journal 01/06/2015
Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion
New York Times 02/03/2015
Overheard: Gilead Needs More Tracks
Wall Street Journal 02/22/2015
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us